FDA Purple Book · Reference family
pivekimab sunirine-pvzy (Decnupaz)
pivekimab sunirine-pvzy is an FDA-licensed reference biologic from AbbVie Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2026
Reference approved
Reference product
351(a)BLA 761460
Decnupaz pivekimab sunirine-pvzy
AbbVie Inc.
- Approved
- May 27, 2026
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for pivekimab sunirine-pvzy, in chronological order.
Reference approval
Approval date of the reference pivekimab sunirine-pvzy product.
2 mo ago
Frequently asked questions
Are there biosimilars approved for pivekimab sunirine-pvzy (Decnupaz)?
No 351(k) biosimilars or interchangeable biosimilars referencing pivekimab sunirine-pvzy are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.